Lymphoma

A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.

No new safety signals were observed with liso-cel, with the therapy showing low rates of severe cytokine release syndrome and neurologic events.

JNJ’4496 at 75 M CAR T cells elicited an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.

Patients with R/R DLBCL given polatuzumab vedotin, rituximab, gemcitabine, and oxaliplatin had an OS of 19.5 months.

Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.

Epcoritamab monotherapy led to long-term disease-free remissions in patients with relapsed/refractory large B-cell lymphoma who achieved complete response at 2 years.

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.

The safety profile for glofitamab plus gemcitabine and oxaliplatin in diffuse large B-cell lymphoma was consistent with known risks for individual drugs.

At a median follow-up of 17.0 months, the sintilimab/chidamide regimen elicited 1-year PFS and OS rates of 95.7% and 95.3%, respectively.

After a median follow-up of 31.2 months, the objective response rate was 97.4% among patients with CLL/SLL.

Treatment with KITE-363 yields no dose-limiting toxicities in a first-in-human phase 1 study.

Tafasitamab is the first CD19 antibody approved in China for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

The FDA’s ODAC convened to discuss the potentially inconsistent treatment effects of glofitamab between regional subgroups in the phase 3 STARGLO trial.

CAR T-cell therapies such as liso-cel and axi-cel in DLBCL were the focal points during an Around the Practice program at the 2025 Tandem Meeting.

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/nivolumab combination regimen, 3 had remission beyond 2 years.

The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.

Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.

Investigators can restart the phase 3 ALLELE trial assessing tabelecleucel for patients with EBV-related posttransplant lymphoproliferative disease.

Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.

Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.

In a multicenter retrospective study authors examined the impact of prior inotuzumab ozogamicin exposure on the outcomes of brexu-cel therapy in adults with R/R B-cell ALL.

Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

At the indication of the FDA and EMA, the phase 3 FLASH2 trial will further evaluate synthetic hypericin in early-stage cutaneous T-cell lymphoma.

Panelists discuss how the treatment landscape for diffuse large B-cell lymphoma (DLBCL) is poised for transformation as novel chimeric antigen receptor T-cell approaches integrate with existing therapies, enhancing efficacy and durability. Insights from Tandem 2025 highlight advancements in cellular therapy, including combinatorial strategies and next-generation chimeric antigen receptor T-cell designs, driving optimism for improved patient outcomes.

Multidisciplinary care is important for all cancer care, specifically bone marrow transplant, stated Nina Wagner-Johnston, MD.

“Recognizing that we could follow immunotherapy with a bone marrow transplant safely was quite important,” Nina Wagner-Johnston, MD, stated.

Results from the phase 3 ECHO trial showed PFS and OS improvements with acalabrutinib in the first-line treatment of MCL compared with standard of care.

Panelists discuss that when selecting a chimeric antigen receptor T-cell (CAR T) product for a patient with an aggressive clinical course and eligibility for cellular therapy, key considerations include urgency, toxicity risks, and efficacy. Factors such as time to manufacture, cytokine release syndrome/immune effector cell–associated neurotoxicity syndrome rates, long-term remission data, and antigen specificity guide decision-making.

Panelists discuss how, when selecting among chimeric antigen receptor T-cell (CAR T) therapies, medical professionals typically consider several key factors: the specific cancer type and its CD19/BCMA expression, FDA-approved indications for each therapy, the patient’s prior treatments and response history, the therapy’s documented efficacy and safety profile, manufacturing time and availability, and center-specific experience with different products. Patient-specific factors like comorbidities and disease burden also influence the decision.

Panelists discuss how the choice between chimeric antigen receptor T-cell (CAR T) therapy and autologous stem cell transplantation (auto-SCT) requires careful evaluation of multiple patient-specific factors. Medical professionals consider disease type and stage, prior treatments, patient age and fitness, cytogenetic risk, donor availability, and timing. CAR T may be preferred for relapsed/refractory cases, whereas transplant remains standard for eligible newly diagnosed patients.